
Sign up to save your podcasts
Or
Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.
See omnystudio.com/listener for privacy information.
4.5
1010 ratings
Tim Boreham, Stockhead's small caps correspondent joins The Australian's Wealth Editor James Kirby on this week's show. They discuss how Biotech gets hit hardest of all, one reason this sector may recover first and three ASX biotech stocks for you to consider.
See omnystudio.com/listener for privacy information.
9 Listeners
19 Listeners
94 Listeners
61 Listeners
3 Listeners
63 Listeners
13 Listeners
1 Listeners
8 Listeners
15 Listeners
17 Listeners
30 Listeners
1 Listeners
3 Listeners
339 Listeners
3 Listeners
26 Listeners
19 Listeners
9 Listeners
37 Listeners
2 Listeners
24 Listeners
57 Listeners
40 Listeners
6 Listeners
18 Listeners
19 Listeners
0 Listeners
7 Listeners